A genetic variant in telomerase reverse transcriptase (TERT) modifies cancer risk in Lynch syndrome patients harbouring pathogenic MSH2 variants

- Wiik, Mariann Unhjem, Evans, Tiffany-Jane, Belhadj, Sami, Bolton, Katherine A., Dymerska, Dagmara, Jagmohan-Changur, Shantie, Capellá, Gabriel, Kurzawski, Grzegorz, Wijnen, Juul T., Valle, Laura, Vasen, Hans F. A., Lubinski, Jan, Scott, Rodney J., Talseth-Palmer, Bente A.

Combined analysis of three lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers

- Talseth-Palmer, Bente A., Wijnen, Juul T., Suchy, Janina, Kurzawski, Grzegorz, The Dutch Cancer Genetics Group,, Spigelman, Allan, Møller, Pål, Morreau, Hans M., Van Wezel, Tom, Lubinski, Jan, Vasen, Hans F. A., Scott, Rodney J., Brenne, Ingvild S., Jagmohan-Changur, Shantie, Barker, Daniel, Ashton, Katie A., Tops, Carli M., Evans, Tiffany-Jane, McPhillips, Mary, Groombridge, Claire

The importance of a large sample cohort for studies on modifier genes influencing disease severity in FAP patients

- Talseth-Palmer, Bente A., Wijnen, Juul T., Van Wezel, Tom, Vasen, Hans F. A., Scott, Rodney J., Andreassen, Eva K., Barker, Daniel, Jagmohan-Changur, Shantie, Tops, Carli M., Meldrum, Cliff, The Dutch Cancer Genetics Group, Spigelman, Allan, Hes, Frederik J.